ft 22 apr 93 survey pharmaceut research develop 11 power econom asset protect term drug patent lengthen govern lengthen patent protect comput fuel inject system compon aircraft undercarriag unit state japan european commun given special treatment specif pharmaceut recent year self interest short answer govern persuad competit capabl stake want throw away power econom asset capabl bring import foreign trade earn us set pace earli 1980 govern accept nation drug firm argument tougher drug test requir consequ longer lead time launch eat patent term damag industri prospect pre launch develop risen three four 1960 around 10 year therebi erod much half product patent life cut lead time seriou option increasingli safeti consciou sector 1984 govern extend length us patent term pharmaceut secur knowledg us compani held lion share us market would princip beneficiari similar logic convinc japanes author extend drug patent life japan 1988 european industri left seriou doubl troubl patent europ still erod long lead time japanes us move left european firm claim systemat disadvantag competit main intern rival consequ begin year new legal instrument come forc ec design specif provid addit intellectu properti protect pharmaceut innov supplementari protect certif spc known give five year market exclus medicin partial compens patent life lost pre launch develop mani 50 new medicin year could qualifi total protect 15 year first launch european firm hold largest share european sale benefit pharmaceut industri produc barrag argument special case contend area industri fund research expens averag new medicin cost ecu200m dollar 242m develop say area innov easi copi medicin therefor vulner post patent competit gener argu product life cycl shorter mani research base industri area longer patent therefor less import real clincher argument provok sceptic industri sector area innov run lengthi post patent control market mani non pharmaceut innov product launch come month patent grant leav 15 year effect patent term contrast ec new spc regul express lengthi develop time new medicin make period effect patent protect patent insuffici cover invest put research independ evid support claim drug need patent product accord uk patent offic 10 per cent patent still renew final year life averag patent across sector maintain 11 year usual abandon product fail overtaken drug firm hand maintain new medicin usual get stride eleventh year patent life one disinterest cross sector compar studi subject also conclud patent field probabl research base pharmaceut industri total depend patent event enlighten self interest convinc member state act research would stifl without patent term reform could stifl europ focu ec measur clear medicin take long time research continu develop commun europ unless cover favour rule provid suffici protect research risk research centr situat member state reloc countri alreadi offer greater protect perceiv risk breakdown develop new drug shift innov away one region toward anoth success research base pharmaceut industri argu case patent protect probabl contain moral combat increas attack price us japan europ patent term restor pleas everyon gener manufactur use trade off us legisl angri get noth ec spc european consum associ complain patient wors competit measur counter balanc longer monopoli spanish govern like mani nation drug compani never support drug patent strongli launch european court action regul even r amp base industri concern new ec law strength spc yet test court law mechan grant spc prove problemat mani applic submit spc sinc begin year reject inadequ nonetheless industri sector show interest emul drug industri achiev europ chemic industri feder cefic declar readi back sector request patent term extens compens time lost pre launch administr procedur first fray pesticid manufactur spc task forc european crop protect associ expect ec propos mid 1993 agro chemic spc futur may question industri catch pharmaceut howev within pharmaceut sector although less level play field drug patent length across three princip drug produc region world sinc start 1993 alreadi sign move make region equal other publish wish list better econom treatment member european drug industri feder efpia conclud catalogu demand mysteri cri present declin explain commun wide mechan need restor normal 20 year period patent protect innov product say drug world brink new round patent term extens leapfrog